Avizakimab, formerly known as BOS161721, represents a novel clinical approach to treating immune-mediated conditions . This biological agent selectively targets interleukin-18 , a key cytokine implicated in https://philiponvi710367.blog5.net/93099134/avizakimab-a-thorough-investigation-into-bos161721-s-potential